VION Biosciences Acquires Prolytix
September 8, 2026
VION Biosciences announced the closing of its acquisition of Prolytix, a provider of regulated bioanalytical and CMC services, research reagents, and custom sample collection products. The deal is intended to strengthen VION’s integrated platform across biopharma services and diagnostic workflow inputs, including regulated large-molecule testing and workflow-critical reagents and IVD materials.
- Targets
- Prolytix
- Sellers
- Edgewater Capital Partners
- Industry
- Biotechnology
- Location
- Ohio, United States
- Transaction Type
- Buyout
Explore More
Build a buyer list for your deal
Find active buyers from recent acquisition patterns and move straight into outreach.